rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Paul A. Wagner

Director and Officer

Company insider

Files Form 4 as: Director and Officer and 10% owner, Forte Biosciences; Chief Financial Officer, Pfenex.

Every Form 4 they filed

In numbers

Trades disclosed
106
Buys
12
Sells
1
Bought
$281K
Sold
$4.3M
Companies
2
Companies where not an officer
0
First trade
2 Feb 2015
Last trade
27 Aug 2026
Last filed
27 Aug 2026

Companies traded

Where they are an officer
Forte BiosciencesDirector, Officer, 10% owner · Biotechnology · last 27 Aug 202612 buys · 1 sell
PfenexOfficer · last 1 Mar 20170 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
27 Aug 2026filed 27 Aug 2026Forte BiosciencesBiotechnologySEC FORM 4 Code U—85,482filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—180,000filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—3,511filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—16,866filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—5,400filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—16,866filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—5,400filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—11,999filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—44,000filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—920,000filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—270,000filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—500,000filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—2,500filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—180,000filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—3,511filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—11,999filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—44,000filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—920,000filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—270,000filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—500,000filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Health Care13

Buys in green, sells in red, by the company’s sector.

Related people

David W. GryskaDirector · Director at Forte Biosciences, filing Form 4 there in the last year
Barbara K. FinckDirector · Director at Forte Biosciences, filing Form 4 there in the last year
Richard G. VincentDirector · Director at Forte Biosciences, filing Form 4 there in the last year
Antony A. RileyChief Financial Officer · Chief Financial Officer at Forte Biosciences, filing Form 4 there in the last year
Stephen K. DobersteinDirector · Director at Forte Biosciences, filing Form 4 there in the last year